REal-world Data of CARdiometabolic ProtEcTion

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07038083

Acronym

RED-CARPET

Enrollment

40000

Registered

2025-06-26

Start date

2014-01-01

Completion date

2044-01-01

Last updated

2025-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiometabolic Diseases

Keywords

Cardiometabolic Diseases, all-cause mortality, Cardiovascular death, Major adverse cardiovascular events

Brief summary

This study is a single-center, historical prospective cohort study including patients diagnosed with metabolic cardiovascular disease, including hypertension, diabetes, obesity, dyslipidemia, hyperuricemia. The primary outcome of the study is all-cause death and cardiovascular death, and the secondary outcome is major adverse cardiovascular events. We aim to measure associations of established or suspected cardiometabolic disease (CMD) risk factors and cardiovascular disease outcomes in a real-world representative cohort.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patients over 18 years old; * Patients with clinical diagnosis of metabolic cardiovascular disease, including hypertension, diabetes, obesity, dyslipidemia, hyperuricemia. 1. Hypertension and normal high blood pressure: Three standardized blood pressure measurements in the clinic on different days, and all the blood pressure values of the three measurements were systolic blood pressure ≥ 120 mmHg and/or diastolic blood pressure ≥ 80 mmHg; 2. Diabetes: ① Typical symptoms of diabetes, and any of the following: ② Random blood glucose ≥ 11.1 mmol/L; ③ Fasting blood glucose (FPG) ≥ 7.0 mmol/L; ④ OGTT 2-hour postprandial blood glucose ≥ 11.1 mmol/L; ⑤ HbA1c ≥ 6.5%; 3. Obesity and overweight: Body mass index (BMI) ≥ 24 kg/m²; 4. Dyslipidemia: At least one of the following lipid indicators is abnormal: ① Total cholesterol (TC) ≥ 6.2 mmol/L; ② Low-density lipoprotein cholesterol (LDL-C) ≥ 4.1 mmol/L; ③ High-density lipoprotein cholesterol (HDL-C) \< 1.0 mmol/L; ④ Triglyceride (TG) ≥ 2.3 mmol/L; ⑤ Lipoprotein(a) ≥ 30 mg/dL; 5. Hyperuricemia: The fasting blood uric acid levels on two different days were \> 420 μmol/L (7 mg/dL) in men and \> 360 μmol/L (6 mg/dL) in women.

Exclusion criteria

* Patients unable to provide informed consent.

Design outcomes

Primary

Measure	Time frame	Description
all-cause mortality	Through study completion, an average of 5 years	Death due to any cause after enrollment
Cardiovascular death	Through study completion, an average of 5 years	Death caused by cardiac causes

Secondary

Measure	Time frame	Description
Major adverse cardiovascular events	Through study completion, an average of 5 years	Including heart failure hospitalization, coronary heart disease, stroke, arrhythmia, valvular heart disease, etc.

Countries

China

Contacts

Primary ContactXiaodong Zhuang

zhuangxd3@mail.sysu.edu.cn+8613760755035

Outcome results